AI Article Synopsis
- Cytomegalovirus (CMV) poses serious health risks for children undergoing transplantation, prompting the need for improved prevention strategies.
- Current CMV prevention methods have limitations, leading researchers to explore new ways to manage CMV infection, particularly through understanding the role of cell-mediated immunity (CMI).
- This article reviews how CMI can be leveraged in transplant patients, discusses available CMI assays, and summarizes studies on their effectiveness in preventing and treating CMV infections.
Article Abstract
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in pediatric transplantation. However, currently utilized CMV prevention paradigms have limitations, leading to research aimed at novel strategies for mitigation of CMV infection. Cell-mediated immunity (CMI) is crucial in controlling CMV infection and the use of CMV-specific CMI assays to guide prevention and treatment of CMV infection in both solid organ transplant and hematopoietic cell transplant recipients shows great promise. In this article, we review the immune response to CMV infection to highlight the rationale for CMI assays, describe available commercial assays and strategies for their use, and summarize relevant literature regarding the use of CMI assays in transplant recipients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpids/piae005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!